XGN - Exagen points to positive economic benefits of Avise

Exagen (XGN) says a new study supports the economic benefits of Avise Lupus testing. Key advancements and findings include that over the four-year time horizon Avise Lupus demonstrated an estimated total direct cost savings of $1,991,152, or $1,991 per patient and year one savings of $655,403 or $655 per eligible patient. "Patients suffering from SLE face significant health disparities, and it is well established that earlier diagnosis often leads to improved patient outcomes. This study quantifies the added economic benefit of early intervention in the treatment of this hard-to-diagnose disease," says Exagen CEO Ron Rocca.Source: Press ReleaseRelated: Exagen inks agreement with Provider Network of America for AVISE tests

For further details see:

Exagen points to positive economic benefits of Avise